IceCure Medical ICCM presented interim results from its ICESECRET kidney cancer cryoablation study at the European ...

Q4 2024 Earnings Call Transcript March 27, 2025 IceCure Medical Ltd misses on earnings expectations. Reported EPS is $-0.08 ...

Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 ...

Somashekharayya Hiremath said As an inventor, I have contributed to multiple projects and patents, shaping energy-based ...

A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

IceCure Medical (ICCM) announced that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses ...

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

IceCure Medical Ltd’s ICCM share price has dipped by 15.54%, which has investors questioning if this is right time to buy.

PR Newswire CAESAREA, Israel IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel /PRNewswire/ -- IceCure Medi ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...